Cargando…
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
BACKGROUND: Impairment of homologous recombination (HR) is found in close to 50 % of ovarian and breast cancer. Tumors with BRCA1 mutations show increased expression of the Insulin-like growth factor type 1 receptor (IGF-1R). We previously have shown that inhibition of IGF-1R results in growth inhib...
Autores principales: | Amin, Oreekha, Beauchamp, Marie-Claude, Nader, Paul Abou, Laskov, Ido, Iqbal, Sanaa, Philip, Charles-André, Yasmeen, Amber, Gotlieb, Walter H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625613/ https://www.ncbi.nlm.nih.gov/pubmed/26510816 http://dx.doi.org/10.1186/s12885-015-1803-y |
Ejemplares similares
-
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
por: Philip, Charles-André, et al.
Publicado: (2017) -
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015) -
Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer
por: Beauchamp, Marie-Claude, et al.
Publicado: (2010) -
Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail
por: Wang, Qiong, et al.
Publicado: (2019) -
PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)